BDR 167
Alternative Names: BDR-167Latest Information Update: 30 Jun 2022
At a glance
- Originator MDimune; NeoCura
- Developer MDimune
- Class Antineoplastics; Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 23 Jun 2022 MDimune has patent protection for BioDrone® in USA, Europe, Japan, Korea and China before June 2022 (MDimune pipeline, June 2022)
- 23 Jun 2022 Early research in Cancer in China (Parenteral)
- 23 Jun 2022 Early research in Cancer in South Korea (Parenteral) before June 2022 (MDimune pipeline, June 2022)